SynthesisBMC cancer2025
A systematic review and meta-analysis of the prevalence and risk factors of prostate cancer in Nigeria.
Synthesis in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate cancer (PCa) remains a leading cause of morbidity and mortality among men worldwide, with significant regional variations in prevalence and risk factors. In Nigeria, data on prostate cancer prevalence remain inconsistent due to limited screening and reporting systems.
aimThis systematic review and meta-analysis aimed to synthesise available evidence on the prevalence and associated risk factors of prostate cancer among Nigerian men.
methodsA systematic search of PubMed, Scopus, Embase, Medline, and CINAHL was conducted using preferred reporting items for systematic reviews and meta-analysis [PRISMA] guidelines. Six high-quality observational studies involving a total sample size of 9,659 men were included. Data were extracted and analysed using a random-effects meta-analysis model using Review Manager software 5.4.1. Risk of bias was assessed using the CASP checklist for observational studies.
resultsThe pooled prevalence of prostate cancer in Nigeria was low but highly heterogeneous across studies (OR = 1.07, 95% CI [1.03, 1.12], p = 0.0006; I² = 100%). Community-based screenings and autopsy studies reported lower prevalence rates compared to hospital-based studies. Age and genetic predisposition were consistent primary risk factors, with lifestyle factors, family history, and delayed healthcare access contributing to advanced disease stages.
conclusionThis meta-analysis found a low but variable prevalence of prostate cancer in Nigeria, driven by differences in screening access and late-stage diagnosis. Age and genetic predisposition were consistent risk factors, alongside modifiable factors such as lifestyle and delayed healthcare seeking. The findings emphasise the need for improved national screening, strengthened cancer registries, genetic counselling, and public health education to reduce the burden of prostate cancer among Nigerian men.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.